Context Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 5
- Market Cap
- $187.4M
- Introduction
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Context Therapeutics Inc.
- Registration Number
- NCT06938711
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
CT-95 in Advanced Cancers Associated With Mesothelin Expression
- Conditions
- Mesothelin-Expressing TumorsEpithelial Ovarian CancerMalignant Pleural Mesothelioma, AdvancedMalignant Peritoneal Mesothelioma, AdvancedLung Adenocarcinoma MetastaticCholangiocarcinoma AdvancedMesothelin-expressing Advanced CancersMesothelin-positive Advanced Malignant Solid TumorsColorectal CancerPancreatic Adenocarcinoma Advanced or Metastatic
- Interventions
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- Context Therapeutics Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT06756035
- Locations
- 🇺🇸
Context Investigational Site, San Antonio, Texas, United States
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Conditions
- Platinum-resistant Ovarian CancerTesticular CancerEndometrial Cancer
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Context Therapeutics Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06515613
- Locations
- 🇺🇸
Context Investigational Site, Dallas, Texas, United States
Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Context Therapeutics Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT05618613
- Locations
- 🇺🇸
Cancer Treatment Centers of America - Western Regional Medical Center, Phoenix, Arizona, United States
🇺🇸Cancer Treatment Centers of America - Midwestern Regional Center, Zion, Illinois, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
News
Context Therapeutics Initiates Phase 1 Trial of CTIM-76 for CLDN6-Positive Cancers
Context Therapeutics has dosed the first patient in a Phase 1 trial of CTIM-76, a bispecific antibody targeting CLDN6-positive gynecologic and testicular cancers.
Context Therapeutics Acquires Rights to BioAtla's Nectin-4 x CD3 TCE, BA3362, for up to $133 Million
Context Therapeutics has acquired the exclusive worldwide license to BioAtla's BA3362, a Nectin-4 x CD3 T-cell engager (TCE), for up to $133 million, including upfront and milestone payments.